Study of CERC-301 for patients with severe major depressive disorder

Trial Profile

Study of CERC-301 for patients with severe major depressive disorder

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2016

At a glance

  • Drugs CERC 301 (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Oct 2016 New trial record
    • 26 Sep 2016 According to Cerecor media release, the company received Fast Track Designation by the US FDA n 2013 for CERC-301, top-line data from this trial is expected in November 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top